Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
69.84
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
359
Open
69.84
Bid (Size)
66.00 (2)
Ask (Size)
71.57 (1)
Prev. Close
69.84
Today's Range
69.84 - 69.84
52wk Range
50.35 - 83.95
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
December 19, 2024
Via
Benzinga
Incyte to Present at Upcoming Investor Conference
December 17, 2024
From
Incyte
Via
Business Wire
Performance
YTD
+6.71%
+6.71%
1 Month
-5.01%
-5.01%
3 Month
+8.92%
+8.92%
6 Month
+9.55%
+9.55%
1 Year
+11.65%
+11.65%
More News
Read More
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
December 17, 2024
Via
ACCESSWIRE
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
December 16, 2024
Via
ACCESSWIRE
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
December 13, 2024
Via
ACCESSWIRE
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
December 13, 2024
Via
The Motley Fool
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
December 10, 2024
From
Incyte
Via
Business Wire
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
December 07, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Incyte
Via
Business Wire
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
November 26, 2024
From
Incyte
Via
Business Wire
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
November 25, 2024
From
Incyte
Via
Business Wire
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
November 24, 2024
Via
Benzinga
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review
November 22, 2024
Via
Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
November 20, 2024
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 19, 2024
Via
Benzinga
Nasdaq Reverses Losses Amid Nvidia Fanfare
November 19, 2024
Via
Talk Markets
Gold Moves Higher; Medtronic Posts Upbeat Results
November 19, 2024
Via
Benzinga
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?
November 19, 2024
Via
Benzinga
Topics
Energy
Exposures
Fossil Fuels
What's Going On With Incyte Shares Tuesday?
November 19, 2024
Via
Benzinga
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 19, 2024
Via
Benzinga
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
November 19, 2024
Via
Benzinga
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views
November 19, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
November 19, 2024
Via
Investor's Business Daily
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
November 19, 2024
Via
Benzinga
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
November 18, 2024
From
Incyte
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.